Despite initial enthusiasm, maintenance strategies following AlloBMT for patients with high-risk MDS and AML-MRC have not led to significant survival benefits [139,140,141], except for specific subsets, such as TP53-mutated diseases [142]. The gene discussed is TP53; the disease is acute myeloid leukemia.